First Tracks Biotherapeutics, Inc., situated in San Diego, California, specializes in pioneering new immunology-based treatments. The firm is actively involved in the discovery and progression of therapeutics aimed at combating autoimmune and inflammatory disorders, currently advancing programs like rosnilimab, ANB033, and ANB101 through their clinical stages.
12 analysts rate TRAX Buy on consensus.
Consensus price target: $75.17 (+59.6% upside from $47.10)
| Fiscal year | Revenue | Revenue YoY | Net income |
|---|---|---|---|
| 2025 | $0 | — | $-166.09M |
| 2024 | $0 | — | $-163.71M |
| 2023 | $0 | — | $-106.15M |
Stock data for TRAX: Summary · AI Insight · Feed · News · Financials · Transcript · SEC Filings · Insider · Politics